Takeda Pharmaceutical Co. Ltd. · TSE:4502
Takeda Pharmaceutical — Q3 2022 Earnings Presentation
57 slides from Takeda Pharmaceutical's earnings presentation, Feb 3, 2022
Slide 1: FY2022 Q3 Earnings Announcement
TSE: 4502 Better health for people, Brighter future for the world FY2022 Q3 Earnings Announcement February 2nd, 2023
Slide 2: Important Notice
IMPORTANT NOTICE For the purposes of this notice, “presentation” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this presentation. This presentation (i
Slide 3: Agenda
Introduction Christophe Weber President & CEO Pipeline Update Andy Plump President, R&D AGENDA Financials Costa Saroukos Chief Financial Officer Q&A Session
Slide 4: Better Health for People, Brighter Future for the World
Better Health for People, Brighter Future for the World Our vision is to discover and deliver life-transforming treatments, guided by our commitment to: We are guided by our values of Takeda-ism which incorporate Integrity, Fairness, Honesty, and PATIENT PEOPLE PLANET Perseverance, with Integrity at
Slide 5: FY2022 Q3 YTD: Executing Strategy & Delivering Results
FY2022 Q3 YTD: EXECUTING STRATEGY & DELIVERING RESULTS Delivering Topline & Core Profit Growth Progress in our Innovative Pipeline • Strong 3Q YTD with Core Revenue growth +4.5% at CER1,2 • QDENGA approved in EU for individuals 4 years of age driven by Growth & Launch Products +20% at CER and older;
Slide 6: Agenda
Introduction Christophe Weber President & CEO Pipeline Update Andy Plump President, R&D AGENDA Financials Costa Saroukos Chief Financial Officer Q&A Session
Slide 7: Updates to Our Pipeline Since FY2022 Q2 Announcement
UPDATES TO OUR PIPELINE SINCE FY2022 Q2 ANNOUNCEMENT • Approved in EU; positive CHMP opinion for dengue-endemic countries that participated in EMA EU-M4all REGULATORY QDENGA • Filed in U.S. and granted priority review by U.S. FDA UPDATES TAK-003 • Review ongoing in endemic countries • Ph-3 trial int
Slide 8: Late-Stage Development Programs with Upcoming NME Filing and Expansion Opportunities
10 LATE-STAGE DEVELOPMENT PROGRAMS WITH UPCOMING NME FILING AND EXPANSION OPPORTUNITIES FY22 FY23 FY24 FY25-27 EXKIVITY 1L NSCLC1 Target Filing (TAK-788) ONCOLOGY modakafusp alfa R/R MM R/R MM Ph2 Start2 Target Filing (TAK-573) 1L CMV3 LIVTENCITY Target Filing R/R CMV3 1L CMV + R/R CMV3 Filed (China
Slide 9: We Continue to Advance Our Mid-Stage Pipeline
WE CONTINUE TO ADVANCE OUR MID-STAGE PIPELINE FY22 FY23 FY24 and Beyond subasumstat 1st POC Solid Tumors Heme and/or Solid Tumors ONCOLOGY Approximately 30 NMEs in CD19+ hematological Ph1 and Ph2 clinical development TAK-007 malignancies RARE GENETICS & Immune Thrombocytopenic Partnerships & targete
Slide 10: Expected LCM Milestones for Growth & Launch and Other Key Products
EXPECTED LCM MILESTONES FOR OUR GROWTH & LAUNCH AND OTHER KEY PRODUCTS IN MAJOR REGIONS FY22 FY23 ICLUSIG Target Filing 1L Ph+ ALL (US) ONCOLOGY CABOMETYX Target Filing CRPC (Japan) RARE GENETICS & TAKHZYRO TAKHZYRO HEMATOLOGY Filed Pediatric HAE (US, EU) Target Filing BMA (US) ENTYVIO ENTYVIO Filed
Slide 11: Key Regulatory Decisions and Phase 3 Readouts in FY22
KEY REGULATORY DECISIONS AND PHASE 3 READOUTS IN FY22 EU approval1 QDENGA Dengue vaccine Endemic country approval1 KEY POTENTIAL LIVTENCITY Post-transplant R/R CMV EU approval REGULATORY APPROVALS Regional approvals2 EXKIVITY 2L EGFR exon20 insertion+ mNSCLC (post-platinum chemo) EU filing withdrawn
Slide 12: TAK-755: Robust Efficacy and Safety in Pivotal Phase 3 Study in cTTP
TAK-755: ROBUST EFFICACY AND SAFETY IN FIRST AND ONLY PIVOTAL PHASE 3 STUDY IN cTTP • cTTP is blood clotting disorder with life-threatening PHASE 1: ADAMTS13 PK PROFILE AFTER TAK-755 INFUSION acute episodes and debilitating chronic symptoms Disease • cTTP: ultra-rare, est. prevalence 2-6 cases/milli
Slide 13: LIVTENCITY: Phase 3 Data in 1L CMV Infection for HSCT
LIVTENCITY: PHASE 3 DATA DEMONSTRATED CLINICALLY MEANINGFUL AND DURABLE EFFECT IN 1L CMV INFECTION FOR HSCT AURORA study primary endpoint: Proportion of patients who achieved confirmed CMV viremia clearance week 8 maribavir vs. valganciclovir Week 8 CMV clearance: 69.6% maribavir vs. 77.4% valgancic
Slide 14: Agenda
Introduction Christophe Weber President & CEO Pipeline Update Andy Plump President, R&D AGENDA Financials Costa Saroukos Chief Financial Officer Q&A Session
Slide 15: Strong YTD Performance with Core Revenue Growth +4.5% at CER
STRONG YTD PERFORMANCE WITH CORE REVENUE GROWTH +4.5% AT CER 1,2 FY2022 Q3 YTD (APR-DEC) • Core Revenue JPY 3,071.3B (USD 23.3B)1,3 grew +4.5% at CER2 driven by Growth & Launch Products +20％ TOPLINE • Reported Revenue grew +13.9% as business momentum and FX more than offset sale of diabetes portfoli
Slide 16: Business Momentum Driving Strong Core Growth at CER
BUSINESS MOMENTUM DRIVING STRONG CORE GROWTH AT CER FY2022 Q3 YTD (APR-DEC) FINANCIAL RESULTS (SUMMARY) (BN YEN, except EPS) REPORTED CORE FY2022 Q3 YTD ACTUAL % CHANGE FY2022 Q3 YTD ACTUAL % CHANGE CER % CHANGE REVENUE 3,071.3 +13.9% 3,071.3 +19.8% +4.5% OPERATING PROFIT 401.9 -13.1% 954.7 +26.0% +
Slide 17: Business Momentum Continues to Drive Strong Revenue Growth
BUSINESS MOMENTUM CONTINUES TO DRIVE STRONG REVENUE GROWTH, ENHANCED BY FX TAILWIND FY2022 Q3 YTD REVENUE VS PRIOR YEAR R EP OR T ED R EVENU E C OR E R EVENU E (BN JPY) +13.9% +19.8% 3,071.3 3,071.3 +393.5 +393.5 2,695.7 +4.5% -133.0 +115.1 2,562.7 +115.1 FY2021 Q3 Sale of Japan Business FX FY2022 Q
Slide 18: Growth & Launch Products Grew +20% at CER in FY22 Q3 YTD
GROWTH & LAUNCH PRODUCTS GREW +20% AT CER IN FY22 Q3 YTD FY2022 Q3 YTD REVENUE PLASMA-DERIVED THERAPIES (PDT) GI RARE DISEASES IMMUNOLOGY ONCOLOGY NEUROSCIENCE OTHER % of Sales: 28% % of Sales: 18% % of Sales: 16% % of Sales: 11% % of Sales: 16% % of Sales: 11% Growth: +11% Growth: +5% Growth: +18%
Slide 19: FY2022 Q3 YTD Operating Profit: Core O.P. Growth of +9.7% at CER
FY2022 Q3 YTD OPERATING PROFIT: CORE O.P. GROWTH OF +9.7% AT CER FY2022 Q3 YTD OPERATING PROFIT VS PRIOR YEAR R EP OR T ED OP ER AT ING P R OF IT C OR E OP ER A T ING P R OF IT (BN JPY) +26.0% -13.1% 462.5 954.7 +123.5 +33.1 -35.5 401.9 +9.7% -131.4 +73.2 +73.2 757.9 FY2021 Gain on sale Business FX
Slide 20: Strong YTD Free Cash Flow of JPY 585.2B
STRONG YTD FREE CASH FLOW OF JPY 585.2B FY2022 Q3 YTD CASH FLOW (BN JPY) Free Cash Flow 585.2 15.2 189.6 32. liquidity of JPY 1.3T (USD 9.5B)1 Total 76.2 76.2 including JPY 700B from undrawn committed line of credit Capex includes and excluding pass-through cash 683.5 GammaDelta and 281.6 Adaptate a
Slide 21: Net Debt/Adjusted EBITDA Reduced to 2.5x
NET DEBT/ADJUSTED EBITDA REDUCED TO 2.5x CHANGE IN NET DEBT Excludes pass-through (BN JPY) cash of JPY 131.3B 3,415.7 Free Cash Flow 585.2 3,233.8 387.5 26.9 83.8 683.5 269.0 76.2 189.6 15.2 Capex includes GammaDelta and Adaptate acquisitions 2022 Operating Divestments Capex Pass-through Dividend Ne
Slide 22: Well-Balanced Maturity Profile; 100% of Debt at Fixed-Rate
WELL-BALANCED MATURITY PROFILE; 100% OF DEBT AT FIXED-RATE WITH WEIGHTED AVERAGE ~2% INTEREST RATE MATURITY LADDER AS OF 31 DECEMBER 2022 1 1,000 800 BILLION JPY 600 PAID OFF IN FY2022 400 HYBRID 200 - ‖ ‖ ‖ ‖ ‖ FY 22 FY 23 FY 24 FY 25 FY 26 FY 27 FY 28 FY 29 FY 30 FY 31 FY 32 FY 40 FY 45 FY 50 FY 6
Slide 23: On Track to Full-Year Management Guidance
ON TRACK TO FULL-YEAR MANAGEMENT GUIDANCE; REPORTED & CORE FORECASTS UNCHANGED (BN YEN, except EPS) REPORTED CORE CORE GROWTH AT CER LATEST FORECAST VS. PRIOR YEAR LATEST FORECAST VS. PRIOR YEAR FY2022 MANAGEMENT GUIDANCE REVENUE 3,930.0 +10.1% 3,930.0 +14.9% Low-single-digit growth OPERATING PROFIT
Slide 24: Topline, Margins & Cash Flow to Deliver Long-Term Value
TOPLINE, MARGINS & CASH FLOW TO DELIVER LONG-TERM VALUE FY2022 Q3 YTD (APR -DEC) OUTLOOK • On track to “low-single digit” full-year FY22 guidance TOPLINE Core Revenue growth at CER +4.5% for Core Revenue growth at CER Core Operating Profit JPY 954.7B (+9.7% growth at CER) • On track to “high-single
Slide 25: Upcoming Takeda Investor Events
UPCOMING TAKEDA INVESTOR EVENTS MARCH 15TH, 2023 WEDNESDAY (7pm EDT start) / QDENGA INVESTOR CALL MARCH 16TH, 2023 THURSDAY (8am JST start) FY2022 Q4 EARNINGS MAY 11th, 2023 4 CONFERENCE CALL (TIME TO BE CONFIRMED) 25
Slide 26: Q&A Session
Q&A SESSION C H RI S T O PH E WE BE R A N D Y PL U MP C O S T A S A RO U K O S RA MO N A S E Q U E I RA Representative Director; Director; President, Director; President, President & CEO Research & Development Chief Financial Officer Global Portfolio Division
Slide 27: Appendix
APPENDIX
Slide 28: GI Franchise Continues to Drive Significant Growth of +11%
G AST R OENT ER OL OG Y ( G I) GI FRANCHISE CONTINUES TO DRIVE SIGNIFICANT GROWTH OF +11% GI PORTFOLIO FY2022 Q3 YTD Revenue JPY 547.9B (+17.4% growth) FY 2022 Q 3 Y T D R E V E N UE • Growth across all markets driven by continued share growth in bio-naïve, amid softness of overall biologic market g
Slide 29: Now Treating Over 4,000 Patients Globally with TAKHZYRO
R AR E D ISEASES NOW TREATING OVER 4,000 PATIENTS GLOBALLY WITH TAKHZYRO; LIVTENCITY LAUNCH ENHANCING PORTFOLIO RARE DISEASES PORTFOLIO FY2022 Q3 YTD Revenue JPY 116.9B (+25.1% growth) FY 2022 Q 3 Y T D R E V E N UE • We observe patients prioritizing effective prevention options like TAKHZYRO as par
Slide 30: PDT Portfolio Continues to Deliver Outstanding Growth
P L ASM A - D ER IVED T H ER AP IES PDT PORTFOLIO CONTINUES TO DELIVER OUTSTANDING GROWTH PDT IMMUNOLOGY PORFOLIO Immunoglobulin Albumin FY 2022 Q 3 Y T D R E V E N UE FY2022 Q3 YTD Revenue JPY 390.5B (+18.9% growth) FY2022 Q3 YTD Revenue JPY 85.5B (+20.5% growth) • Strong demand globally, especiall
Slide 31: Oncology Growth Impacted by Velcade Generics
ONC OL OG Y ONCOLOGY GROWTH IMPACTED BY VELCADE GENERICS; PORTFOLIO EXCLUDING VELCADE GREW +7% AT CER ONCOLOGY PORTFOLIO FY 2022 Q 3 Y T D R E V E N UE • Approved in China for EGFR Exon20 Insertion+ NSCLC (BN JPY) 400 -13% • Included in the 2022 National Reimbursement Drug List in China 350 • Contin
Slide 32: Neuroscience Franchise Continues Rebound from COVID-19 Impact
NEU R OSC IENC E NEUROSCIENCE FRANCHISE CONTINUES REBOUND FROM COVID-19 IMPACT N EURO SCIENCE P O RTFOLIO FY2022 Q3 YTD Revenue JPY 335.4B (+13.5% growth) FY 2022 Q 3 Y T D R E V E N UE • Growth in FY2022 driven by the expanding ADHD adult population in the U.S. (BN JPY) • Ramping down product-relat
Slide 33: Consolidated Development Pipeline by Phase
CONSOLIDATED DEVELOPMENT PIPELINE BY PHASE PHASE 3 (7 NMEs + 22 LCMs) FILED (1 NME + 10 LCMs) EXKIVITY® ICLUSIG® CABOMETYX® ZEJULA® 1L NSCLC EGFR mCRPC combo exon 20 1L Ph+ ALL (US) w/atezolizumab (JP) Breast cancer (JP) NINLARO® NINLARO® relugolix ONCOLOGY Maint. ND MM no SCT Maint. ND MM Prostate
Slide 34: Consolidated Development Pipeline by Phase
CONSOLIDATED DEVELOPMENT PIPELINE BY PHASE PHASE 1 (16 NMEs + 1 LCM) PHASE 2 (18 NMEs + 2 LCMs) TAK-102 TAK-103 TAK-186 TAK-940 modakafusp alfa modakafusp alfa subasumstat TAK-007 CD19+ hematologic CD19+ hematologic Solid tumors Solid tumors EGFR Solid Tumor1 malignancies Solid tumors R/R MM Multipl
Slide 35: Glossary of Abbreviations
GLOSSARY OF ABBREVIATIONS Regional Abbreviations: EE H erosive esophagitis healing MAOB monoamine oxidase B POGD post-operative gastrointestinal dysfunction CN: China; EU: Europe; JP: Japan; US: United States of America EE M erosive esophagitis maintenance MDD major depressive disorder PONV post-ope
Slide 36: Financial Appendix
FINANCIAL APPENDIX Definition of Non-IFRS Measures Definition of Core Financial Measures, Constant Exchange Rate change, and Free Cash Flow A-1 Definition of EBITDA/Adjusted EBITDA and Net Debt A-2 Reconciliations and Other Financial Information FY2022 Q3 YTD Reported Results with Actual and CER % C
Slide 37: Definition of Core Financial Measures, CER, and Free Cash Flow
Definition of Core Financial Measures, Constant Exchange Rate change, and Free Cash Flow Core Revenue represents revenue adjusted to exclude significant items unrelated to Takeda’s core operations. Core Operating Profit represents net profit adjusted to exclude income tax expenses, the share of prof
Slide 38: Definition of EBITDA/Adjusted EBITDA and Net Debt
Definition of EBITDA/Adjusted EBITDA and Net Debt We present EBITDA and Adjusted EBITDA because we believe that these measures are useful to investors as they are frequently used by securities analysts, investors and other interested parties in the evaluation of companies in our industry. We further
Slide 39: FY2022 Q3 YTD Reported Results with Actual and CER % Change
FY2022 Q3 YTD Reported Results with Actual and CER % Change vs. PY FY2021 FY2022 (Billion JPY) Q3 YTD Q3 YTD ACTUAL % CHANGE CER % CHANGE*1 Revenue 2,695.7 3,071.3 375.6 13.9% (0.7)% Cost of sales (798.5) (934.3) (135.8) (17.0)% (3.4)% Gross profit 1,897.3 2,137.0 239.8 12.6% (2.4)% Margin 70.4 % 69
Slide 40: FY2022 Q3 (Oct-Dec) Reported Results with Actual and CER % Change
FY2022 Q3 (Oct-Dec) Reported Results with Actual and CER % Change vs. PY FY2021 Q3 FY2022 Q3 (Billion JPY) (Oct-Dec) (Oct-Dec) ACTUAL % CHANGE CER % CHANGE*1 Revenue 901.3 1,096.6 195.3 21.7% 2.6% Cost of sales (281.4) (336.0) (54.6) (19.4)% (2.3)% Gross profit 619.9 760.6 140.7 22.7% 2.7% Margin 68
Slide 41: FY2022 Q3 YTD Core Results with Actual and CER % Change
FY2022 Q3 YTD Core Results with Actual and CER % Change vs. PY FY2021 FY2022 (Billion JPY) Q3 YTD Q3 YTD ACTUAL % CHANGE CER % CHANGE*1 Revenue 2,562.7 3,071.3 508.6 19.8% 4.5% Cost of sales (764.7) (901.7) (137.0) (17.9)% (4.2)% Gross profit 1,798.0 2,169.6 371.7 20.7% 4.6% Margin 70.2 % 70.6 % 0.5
Slide 42: FY2022 Q3 (Oct-Dec) Core Results with Actual and CER % Change
FY2022 Q3 (Oct-Dec) Core Results with Actual and CER % Change vs. PY FY2021 Q3 FY2022 Q3 (Billion JPY) (Oct-Dec) (Oct-Dec) ACTUAL % CHANGE CER % CHANGE*1 Revenue 901.3 1,096.6 195.3 21.7% 2.6% Cost of sales (270.6) (330.1) (59.5) (22.0)% (4.7)% Gross profit 630.7 766.4 135.7 21.5% 1.7% Margin 70.0 %
Slide 43: FY2022 Q3 YTD Reconciliation from Reported to Core
FY2022 Q3 YTD Reconciliation from Reported to Core REPORTED TO CORE ADJUSTMENTS (Billion JPY) REPORTED Amortization of Impairment of Other CORE intangible intangible operating income/ Others assets assets expenses Revenue 3,071.3 3,071.3 Cost of sales (934.3) 32.6 (901.7) Gross profit 2,137.0 32.6 2
Slide 44: FY2022 Q3 (Oct-Dec) Reconciliation from Reported to Core
FY2022 Q3 (Oct-Dec) Reconciliation from Reported to Core REPORTED TO CORE ADJUSTMENTS (Billion JPY) REPORTED Amortization of Impairment of Other CORE intangible intangible operating income/ Others assets assets expenses Revenue 1,096.6 1,096.6 Cost of sales (336.0) 5.9 (330.1) Gross profit 760.6 5.9
Slide 45: FY2021 Q3 YTD Reconciliation from Reported to Core
FY2021 Q3 YTD Reconciliation from Reported to Core REPORTED TO CORE ADJUSTMENTS (Billion JPY) REPORTED Other Irish CORE Amortization of Impairment of Sale of Japan TEVA JV related operating Tax intangible intangible diabetes accounting Others income/ Assessment assets assets portfolio adjustments ex
Slide 46: FY2021 Q3 (Oct-Dec) Reconciliation from Reported to Core
FY2021 Q3 (Oct-Dec) Reconciliation from Reported to Core REPORTED TO CORE ADJUSTMENTS (Billion JPY) REPORTED Other Irish CORE Amortization of Impairment of Sale of Japan TEVA JV related operating Tax intangible intangible diabetes accounting Others income/ Assessment assets assets portfolio adjustme
Slide 47: Free Cash Flow
Free Cash Flow FY2021 FY2022 (Billion JPY) Change versus the previous year Q3 YTD Q3 YTD Net profit 241.5 285.9 44.4 18.4% Depreciation, amortization and impairment loss 445.5 545.0 99.4 Decrease (increase) in trade working capital 41.2 (172.4) (213.5) Income taxes paid (107.2) (173.4) (66.1) Tax re
Slide 48: FY2022 Q3 YTD Net Debt to Adjusted EBITDA
FY2022 Q3 YTD Net Debt to Adjusted EBITDA NET DEBT/ADJUSTED EBITDA RATIO NET INCREASE (DECREASE) IN CASH FY2022 FY2021 FY2022 Change versus the (Billion JPY) (Billion JPY) Q3 YTD Q3 YTD Q3 YTD previous year Cash and cash equivalents*1 553.8 Net cash from operating activities 747.5 683.5 (64.1) (8.6)
Slide 49: FY2021 Net Debt to Adjusted EBITDA
FY2021 Net Debt to Adjusted EBITDA NET DEBT/ADJUSTED EBITDA RATIO NET INCREASE (DECREASE) IN CASH (Billion JPY) FY2021 (Billion JPY) FY2020 FY2021 vs. PY Cash and cash equivalents*1 642.2 Net cash from operating activities 1,010.9 1,123.1 112.2 11.1 % Book value debt on consolidated statements of (4
Slide 50: FY2022 Q3 YTD and FY2021 Q3 YTD Net Profit to Adjusted EBITDA Bridge
FY2022 Q3 YTD and FY2021 Q3 YTD Net Profit to Adjusted EBITDA Bridge FY2021 FY2022 (Billion JPY) Change versus the previous year Q3 YTD Q3 YTD Net profit 241.5 285.9 44.4 18.4% Income tax expenses 115.1 41.3 Depreciation and amortization 430.9 503.0 Interest expense, net 86.7 86.0 EBITDA 874.2 916.2
Slide 51: FY2022 Q3 YTD Net Profit to Adjusted EBITDA LTM Bridge
FY2022 Q3 YTD Net Profit to Adjusted EBITDA LTM Bridge FY2021 FY2021 FY2022 FY2022 (Billion JPY) Full Year Q3 YTD Q3 YTD Q3 YTD LTM*1 (Apr-Mar) (Apr - Dec) (Apr - Dec) (Jan-Dec) Net profit 230.2 241.5 285.9 274.5 Income tax expenses 72.4 115.1 41.3 (1.4) Depreciation and amortization 583.2 430.9 503
Slide 52: FX Rates and FY2022 Currency Sensitivity
FX Rates and FY2022 Currency Sensitivity Average Exchange Rates vs. JPY Impact of depreciation of yen from October 2022 to March 2023 on FY2022 forecast (100 million JPY) Core FY2021 FY2022 FY2022 Operating Revenue Net Profit Operating Actual Actual Assumption Profit (IFRS) (IFRS) Profit (Apr-Dec) (
Slide 53: CAPEX, Depreciation and Amortization and Impairment Losses
CAPEX, Depreciation and Amortization and Impairment Losses FY2022 Latest FY2021 FY2022 (Billion JPY) FY2021 vs. PY Forecast Q3 YTD Q3 YTD (Oct 27, 2022) Capital expenditures*1 186.0 134.2 189.6 55.4 41.3% 260.0 to 310.0 Tangible assets 123.3 87.7 104.9 17.2 19.6% Intangible assets 62.8 46.5 84.7 38.
Slide 54: FY2022 Detailed Forecast
FY2022 Detailed Forecast FY2022 FY2022 FY2021 Latest Latest (BN JPY) Actual Forecast Forecast (Oct 27, 2022) % change vs. PY Revenue 3,569.0 3,930.0 10.1% R&D expenses (526.1) (620.0) (17.9)% Amortization of intangible assets associated with products (418.8) (480.0) (14.6)% Impairment losses on inta
Slide 55: FY2022 Core Operating Profit Adjustment Items & Cash Flow Forecast
FY2022 Core Operating Profit Adjustment Items & Cash Flow Forecast CORE OPERATING PROFIT ADJUSTMENT ITEMS FY2022 FY2022 Latest (Billion JPY) Q3 YTD Forecast (Oct 27, 2022) Amortization of intangible assets associated with products 370.6 480.0 Of which Shire-acquisition related 300.9 390.0 Impairment
Slide 56: FY2022 Reconciliation from Reported Operating Profit to Core Operating Profit Forecast
FY2022 Reconciliation from Reported Operating Profit to Core Operating Profit Forecast REPORTED TO CORE ADJUSTMENTS Other (Billion JPY) REPORTED Amortization of Impairment of CORE operating intangible intangible Others income assets assets (expenses) Revenue 3,930.0 3,930.0 Cost of sales 28.0 Gross
Slide 57: © 2023 Takeda Pharmaceutical Company Limited. All rights reserved.
© 2023 Takeda Pharmaceutical Company Limited. All rights reserved.
Takeda Pharmaceutical Company — Q3 2022 Earnings Presentation on 6ix